乳腺癌中的APOBEC:瘤进化和治疗反应中的双重参与者
Haiqi Lu1, Zelin Lu1, Yufei Wang1
1Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Frontiers in molecular biosciences
|May 13, 2025
概括
APOBEC酶家族通过改变DNA和塑造免疫反应来驱动乳腺癌. APOBEC签名可以预测免疫治疗的治疗成功.
科学领域:
- 生物化学 生物化学
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- APOBEC酶对于DNA/RNA编辑至关重要.
- 它们在乳腺癌中起着双重作用,促进异质性和影响免疫微环境.
研究的目的:
- 审查APOBEC在乳腺癌中的分子机制.
- 探索临床影响和治疗策略.
主要方法:
- 文献综述和关于乳腺癌中APOBEC酶的当前研究的综合.
主要成果:
- 由APOBEC驱动的突变与高瘤突变负担 (TMB),复制压力和对免疫检查点抑制剂 (ICI) 的反应相关.
- 这些突变也会导致内分泌疗法耐药性和瘤进化.
- APOBEC签名显示出作为ICI疗效预测生物标志物的潜力.
结论:
- APOBEC酶在乳腺癌中起着复杂的作用,影响瘤的进展和免疫反应.
- 准APOBEC活动提供了潜在的治疗途径,如ATR抑制和超变异性免疫疗法.
- 利用APOBEC的双重性可以推进乳腺癌治疗的精密瘤学.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Immunotherapy
411
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
411
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K


